Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 10466
TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489625(US10961252, Cmp No. 13 | (3R)-1-(8-(4-amino- 8-flu...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489628(US10961252, Cmp No. 16 | 4-((1R)-3-(8-(4-amino- 8-...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489631(US10961252, Cmp No. 18 | 1-(4-(4-amino-8-fluoro- 6...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489629(US10961252, Cmp No. 17 | (R)-4-(3-(4-(4-amino- 8-f...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489636(US10961252, Cmp No. 22 | imino(4-((2S,4R)- 1-((5-m...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489641(US10961252, Cmp No. 26 | (4-(1-((5-methoxy-7- meth...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489640(US10961252, Cmp No. 25 | imino(4-(1-((5- methoxy-7...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489643(US10961252, Cmp No. 28 | 4-(1-((5-methoxy-7- methy...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489642(US10961252, Cmp No. 27 | N-hydroxy-4-(1-((5- metho...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489645(US10961252, Cmp No. 30 | (S)-imino(4-((2S,4R)- 1-(...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489644(US10961252, Cmp No. 29 | (4-((2S,4R)-1-((5- methox...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489648(US10961252, Cmp No. 32 | (4-((2S,4R)-1-((5- methox...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489646(US10961252, Cmp No. 31 | (R)-imino(4-((2S,4R)- 1-(...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489650(US10961252, Cmp No. 34 | 4-((2S,4R)-1-((5- methoxy...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489613(US10961252, Cmp No. 3 | 1-(4-(4-amino-8- fluoro-6,...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489612(US10961252, Cmp No. 2 | 1-(4-(4-amino-8- fluoro-6,...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489614(US10961252, Cmp No. 4 | (R)-1-(4-(4-amino-8- fluor...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489623(US10961252, Cmp No. 10 | (3R)-1-(4-(4-amino- 8-flu...)
Affinity DataIC50: 1.00E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489649(US10961252, Cmp No. 33 | (4-((2R,4S)-1-((5- methox...)
Affinity DataIC50: 5.50E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489616(US10961252, Cmp No. 5 | (R)-1-(4-(4-amino- 8-fluor...)
Affinity DataIC50: 5.50E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489617(US10961252, Cmp No. 6 | (R)-4-(4-amino-8- fluoro-6...)
Affinity DataIC50: 5.50E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489622(US10961252, Cmp No. 9 | 4-(4-amino-8-fluoro- 6,7-d...)
Affinity DataIC50: 5.50E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489624(US10961252, Cmp No. 12 | (R)-1-(4-(8-amino- 2,2,4-...)
Affinity DataIC50: 5.50E+3nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489626(US10961252, Cmp No. 14 | 1-(3-(4-amino-8- fluoro-6...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489627(US10961252, Cmp No. 15 | (3R)-1-(5-(4-amino- 8-flu...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489611(US10961252, Cmp No. 1 | 1-(4-(4-amino-8- fluoro-6,...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489634(US10961252, Cmp No. 20 | (1R,4s)-4-((S)-1-((5- met...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489651(US10961252, Cmp No. 35 | 4-((2R,4R)-1-((5- methoxy...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489632(US10961252, Cmp No. 19 | 4-(4,4-difluoro-1-((5- me...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489635(US10961252, Cmp No. 21 | 4-((2S,4R)-1-((5- methoxy...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489638(US10961252, Cmp No. 24 | 4-((2S,4R)-1-((5- methoxy...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489618(US10961252, Cmp No. 7 | 4-(4-amino-8-fluoro- 6,7-d...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489637(US10961252, Cmp No. 23 | imino(4-((2R,4S)-1- ((5-m...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent

TargetCobra venom factor/Complement factor B/Complement factor D(Monocled cobra)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM489619(US10961252, Cmp No. 8 | (R)-4-(4-amino-8- fluoro-6...)
Affinity DataIC50: 1.00E+4nMAssay Description:CVF-Bb complex is prepared from purified cobra venom factor (1 μM); human Complement factor B and human Complement factor D are available from a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
US Patent